United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - bromocriptine mesilate - oral tablet - 2.5mg

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - bromocriptine mesilate 11.48mg equivalent to 10 mg bromocryptine - tablet - 10 mg - active: bromocriptine mesilate 11.48mg equivalent to 10 mg bromocryptine excipient: butylated hydroxyanisole lactose monohydrate magnesium stearate maize starch sodium starch glycolate sunset yellow fcf tragacanth

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - bromocriptine mesilate 2.87mg equivalent to bromocriptine 2.5 mg - tablet - 2.5 mg - active: bromocriptine mesilate 2.87mg equivalent to bromocriptine 2.5 mg excipient: colloidal silicon dioxide disodium edetate dihydrate lactose monohydrate magnesium stearate maize starch maleic acid povidone

Ireland - English - HPRA (Health Products Regulatory Authority)

meda health sales ireland limited - bromocriptine mesilate - tablets - 2.5 milligram - bromocriptine

Ireland - English - HPRA (Health Products Regulatory Authority)

meda health sales ireland limited - bromocriptine mesilate - capsules hard - 5 mg milligram - bromocriptine

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - bromocriptine mesilate, quantity: 2.87 mg (equivalent: bromocriptine, qty 2.5 mg) - tablet, uncoated - excipient ingredients: maize starch; lactose monohydrate; disodium edetate; colloidal anhydrous silica; maleic acid; magnesium stearate - prevention of onset of lactation in the puerperium for clearly defined medical reasons. therapy should be continued for 14 days to prevent rebound lactation. parlodel should not be used to suppress established lactation. treatment of hyperprolactinaemia where surgery and/or radiotherapy are not indicated or have already been used with incomplete resolution. precautions should be taken to ensure that the hyperprolactinaemia is not due to severe primary hypothyroidism. where the cause of hyperprolactinaemia is a prolactin-secreting microadenoma or macroadenoma, parlodel is indicated for conservative treatment; prior to surgery in order to reduce tumour size and to facilitate removal; after surgery if prolactin level is still elevated. adjunctive therapy in the management of acromegaly when: (1) the patient refuses surgery and/or radiotherapy; (2) surgery and/or radiotherapy has been unsuccessful or full effects are not expected for some months; (3) a manifestation of the acromegaly needs to be brought under con

Malta - English - Medicines Authority

generis farmaceutica s.a. rua joao de deus, 19 , 2700-487 amadora, portugal - bromocriptine - tablet - bromocriptine 2.5 mg - other gynecologicals

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - bromocriptine mesilate - tablet - 2.5 milligram(s) - prolactine inhibitors; bromocriptine

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - bromocriptine mesilate - capsule, hard - 5 mg milligram(s) - prolactine inhibitors; bromocriptine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris healthcare sa-nv - bromocriptine mesilate 2,87 mg - eq. bromocriptine 2,5 mg - tablet - 2,5 mg - bromocriptine mesilate 2.87 mg - bromocriptine